There is something poetic about a company named Synchrony showing up right when respiratory care needs better timing, better rhythm, and a lot less noise. Synchrony Medical did not emerge from a...
There is something poetic about a company named Synchrony showing up right when respiratory care needs better timing, better rhythm, and a lot less noise. Synchrony Medical did not emerge from a pitch deck fantasy or a conference room fever dream. It was conceived in early 2020, in the middle of a global respiratory crisis, inside Sheba Medical Center and the MEDX Xelerator, where clinical reality has a habit of humbling theory fast and separating ideas from outcomes.
The founders did not come to play startup cosplay. Anat Shani, CEO and co-founder, brought more than a decade of wearable medical device execution and the discipline that comes from actually shipping hardware, not just talking about it. Alongside her were Prof. Ori Efrati and Dr. Moshe Ashkenazi, senior pediatric pulmonologists at Sheba Medical Center, who brought lungs, airflow mechanics, mucus physiology, and patient truth into the room. Gil Sokol grounded it all with physiotherapy pragmatism. Four disciplines, one shared intolerance for ineffective respiratory therapy and patient noncompliance disguised as standard of care.
Out of that friction came LibAirty, an airway clearance system that understands breathing is not just mechanical, it is behavioral, physiological, and deeply human. App guided breathing synchronized with targeted chest compressions sounds simple until you realize decades of autogenic drainage know-how were compressed into a system patients can actually use at home without a therapist standing over them. In comparative clinical studies at Sheba Medical Center and MUSC, LibAirty delivered 2x sputum clearance versus traditional vest therapy, with p<0.0001. That is not marketing. That is math. Patients noticed too, reporting higher satisfaction and better adherence, which is the quiet metric that changes outcomes. FDA 510(k) clearance landed in December 2024, followed by a U.S. launch in October 2025. No victory laps. Just execution. The real signal came January 12, 2026, when Synchrony Medical secured a $2M coordinated investment from the New Jersey Innovation Evergreen Fund and Edge Medical Ventures. One public private fund designed to anchor serious innovation in New Jersey. One medtech venture studio built by people who have carried devices from bench to bedside. When both lean in, it is not applause. It is conviction. Edge Medical Ventures Managing Partner Shai Policker pointed to clear signs of commercial traction, and that matters in an airway clearance market crowded with heavy, loud legacy systems. LibAirty is lighter, quieter, and clinically louder where it counts. COPD. Bronchiectasis. Cystic fibrosis. Chronic mucus plugging. These are not niche problems. They are daily realities for millions of patients who would rather breathe than negotiate with equipment. Now operating between Or Yehuda and Jersey City, Synchrony Medical sits at the intersection of clinical rigor and commercial urgency. Growth capital is flowing where it belongs: U.S. expansion, real-world evidence, product refinement, and patient access. No theatrics. Just synchronized execution.